Drugs / Minoxidil
last change Aug 2026 re-read 2 minutes ago

Minoxidil

Small molecule targets AR via inhibition

Developed for
androgenetic alopecia · alopecia · baldness, male pattern · hypotrichosis · chemotherapy-induced alopecia · acne · childhood malignant neoplasm · endocrine alopecia
+7 more · graying of hair, precocious · ovarian carcinoma · Tented eyebrows · Williams syndrome · alopecia areata · central centrifugal cicatricial alopecia · hypertensive disorder
Investigated by
Mae Fah Luang University Hospital · Aneira Pharma, Inc. · Beijing Dayspring Pharmaceutical Technology Co., Ltd · Cantabria Labs · Eurofarma Laboratorios S.A. · Galderma R&D
+31 more · Indonesia University · Johnson & Johnson Consumer and Personal Products Worldwide · Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. · Ohio State University Comprehensive Cancer Center · Samson Clinical Operations Pty Ltd · Astrum CRO, S.L. · Bioskin GmbH · Chang Gung Memorial Hospital · Cures Within Reach · DataPharm Australia, CMAX Clinical Research, Agilex Australia · Dr. dr. Lili Legiawati, SpKK(K) · Duke University · Farid Masoud · Hospices Civils de Lyon · Jinnah Postgraduate Medical Centre · Kasiak Research Pvt. Ltd. · Kasr El Aini Hospital · Loyola University · Mayo Clinic · Medical University of South Carolina · Memorial Sloan Kettering Cancer Center · Ministry of Education, Culture, Research, and Technology, Republic of Indonesia · Mohammed Abd El Mawgoud Amer · Northwestern University · PT. Kimia Farma (Persero) Tbk · Sheikh Zayed Federal Postgraduate Medical Institute · Siriraj Hospital · Southern Medical University, China · University of British Columbia · University of Minnesota · Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) MEN'S ROGAINE 2014-02-28 fda.gov
Label expansions (2) US (FDA) ROGAINE (FOR WOMEN) 1991-08-13 – 1996-02-09 fda.gov
Approved US (FDA) LONITEN 1979-10-18 fda.gov

Trials 43 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT05790941 Mar → Jun 2023 hypotrichosis Aneira Pharma, Inc. Unknown No outcome recorded
Phase 0 NCT05417308 Mar 2023 → Dec 2027 expected endocrine alopecia, female breast carcinoma Ohio State University Comprehensive Cancer Center Recruiting No outcome recorded
Phase 0 NCT03831334 Apr 2019 → Jan 2024 overdue chemotherapy-induced alopecia Northwestern University Active not recruiting No outcome recorded
Phase 15 trials
Phase 1 NCT07264790 Mar 2026 → Sep 2027 expected Duke University Recruiting No outcome recorded
Phase 1 NCT06679556 Nov → Dec 2024 Samson Clinical Operations Pty Ltd Completed No outcome recorded
Phase 1 NCT07038941 Mar → Jun 2024 androgenetic alopecia Beijing Dayspring Pharmaceutical Technology Co., Ltd Completed No outcome recorded
Phase 1 NCT06015516 Feb → Mar 2024 Cantabria Labs Completed No outcome recorded
Phase 1 NCT05864885 Jun → Jul 2023 androgenetic alopecia Aneira Pharma, Inc. Unknown No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT06108193 Jul → Dec 2023 acne Chang Gung Memorial Hospital Unknown No outcome recorded
Phase 1/2 NCT03488108 Jan 2017 → May 2018 alopecia Mayo Clinic Completed No outcome recorded
Phase 1/2 NCT01650272 Jun 2012 → Feb 2013 Siriraj Hospital Unknown No outcome recorded
Phase 1/2 NCT01643629 Jan → Oct 2012 androgenetic alopecia Kasiak Research Pvt. Ltd. Unknown No outcome recorded
Phase 27 trials
Phase 2 NCT07594678 Jul 2026 → Dec 2027 expected chemotherapy-induced alopecia, female breast carcinoma Ohio State University Comprehensive Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07076706 Dec 2024 → Aug 2025 baldness, male pattern Beijing Dayspring Pharmaceutical Technology Co., Ltd Completed No outcome recorded
Phase 2 NCT05778825 Mar 2023 → Mar 2027 expected alopecia, childhood malignant neoplasm Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT03852992 Sep 2022 → Jul 2023 baldness, male pattern University of Minnesota Withdrawn No outcome recorded
Phase 2 NCT05272462 Dec 2021 → Dec 2024 ovarian carcinoma Loyola University Unknown No outcome recorded
Phase 2 NCT00876200 Mar 2009 → Feb 2015 Williams syndrome Hospices Civils de Lyon Completed No outcome recorded
Phase 2 NCT00175617 Sep 2005 → Mar 2009 androgenetic alopecia University of British Columbia Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05990400 May → Oct 2023 androgenetic alopecia Indonesia University Unknown No outcome recorded
Phase 312 trials
Phase 3 NCT07529977 Jan 2027 → Oct 2028 expected androgenetic alopecia Eurofarma Laboratorios S.A. Not yet recruiting No outcome recorded
Phase 3 NCT07273799 Dec 2025 → May 2026 overdue androgenetic alopecia Sheikh Zayed Federal Postgraduate Medical Institute Not yet recruiting No outcome recorded
Phase 3 NCT06924632 Jul 2025 → May 2026 baldness, male pattern Samson Clinical Operations Pty Ltd Completed No outcome recorded
Phase 3 NCT07080931 Feb 2025 → Dec 2027 expected androgenetic alopecia Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. Recruiting No outcome recorded
Phase 3 NCT05888922 Oct 2024 → Oct 2026 expected androgenetic alopecia Cantabria Labs Recruiting No outcome recorded
Phase 3 NCT05989165 Jun → Sep 2023 androgenetic alopecia Indonesia University Completed No outcome recorded
Phase 3 NCT04721548 Mar 2023 → Mar 2024 alopecia Eurofarma Laboratorios S.A. Completed No outcome recorded
Phase 3 NCT03753113 Nov 2018 → Sep 2019 androgenetic alopecia Farid Masoud Completed No outcome recorded
Phase 3 NCT01391156 Mar 2011 → Mar 2012 androgenetic alopecia Mae Fah Luang University Hospital Completed No outcome recorded
Phase 3 NCT01226459 Sep 2010 → Aug 2011 androgenetic alopecia Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. Completed No outcome recorded
Phase 45 trials
Phase 4 NCT06813963 Feb 2025 → Feb 2026 graying of hair, precocious Southern Medical University, China Completed No outcome recorded
Phase 4 NCT02283645 Jan → Aug 2015 Mae Fah Luang University Hospital Unknown No outcome recorded
Phase 4 NCT02275832 Nov 2014 → Mar 2015 Mae Fah Luang University Hospital Completed No outcome recorded
Phase 4 NCT01924000 Dec 2013 → Apr 2014 Tented eyebrows, hypotrichosis Mae Fah Luang University Hospital Completed No outcome recorded
Phase 4 NCT01672307 Sep → Nov 2012 hypotrichosis Mae Fah Luang University Hospital Completed No outcome recorded
Phase not applicable6 trials
NCT07563036 Feb → Oct 2026 expected androgenetic alopecia Kasr El Aini Hospital Recruiting No outcome recorded
NCT07018349 Jun → Sep 2025 overdue androgenetic alopecia Jinnah Postgraduate Medical Centre Not yet recruiting No outcome recorded
NCT06066827 Aug → Nov 2023 androgenetic alopecia Dr. dr. Lili Legiawati, SpKK(K) Unknown No outcome recorded
NCT05369481 Mar → Aug 2022 androgenetic alopecia Mohammed Abd El Mawgoud Amer Unknown No outcome recorded
NCT02460497 May → Sep 2015 androgenetic alopecia Galderma R&D Completed No outcome recorded
NCT02460289 May → Nov 2015 androgenetic alopecia Galderma R&D Completed No outcome recorded
Also used as a comparator or background therapy in 44 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT07012486 Comparator Jun 2025 → May 2026 overdue androgenetic alopecia Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 0 NCT06527729 Comparator Jul 2021 → Jun 2022 alopecia areata Assiut University Completed No outcome recorded
Phase 11 trial
Phase 1 NCT02824380 Background Jul → Oct 2016 androgenetic alopecia Dong-A ST Co., Ltd. Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT07203599 Comparator Sep 2025 → Oct 2026 expected androgenetic alopecia Shenzhen People's Hospital Recruiting No outcome recorded
Phase 1/2 NCT06333600 Comparator May 2023 → Apr 2024 androgenetic alopecia, skin disorder Sohag University Unknown No outcome recorded
Phase 1/2 NCT05636904 Comparator Dec 2022 → Mar 2024 androgenetic alopecia Dermaliq Therapeutics, Inc. Completed No outcome recorded
Phase 1/2 NCT02280603 Comparator Jan → Dec 2014 androgenetic alopecia Dong-A ST Co., Ltd. Completed No outcome recorded
Phase 29 trials
Phase 2 NCT07548918 Background May 2026 → Feb 2027 expected vitiligo Sohag University Not yet recruiting No outcome recorded
Phase 2 NCT07370519 Comparator Jan 2026 → Jan 2027 expected androgenetic alopecia Shenzhen People's Hospital Recruiting No outcome recorded
Phase 2 NCT07011485 Comparator May → Aug 2025 overdue androgenetic alopecia PDFE Pharma Innovations FZCO Active not recruiting No outcome recorded
Phase 2 NCT06826001 Comparator Feb → Jul 2025 overdue androgenetic alopecia Sheikh Zayed Medical College Not yet recruiting No outcome recorded
Phase 2 NCT02279823 Comparator Oct 2014 → Dec 2015 androgenetic alopecia Intrepid Therapeutics, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04481412 Background Jul 2020 → Nov 2021 androgenetic alopecia Cairo University Completed No outcome recorded
Phase 37 trials
Phase 3 NCT07435012 Comparator Apr 2026 → Dec 2027 expected androgenetic alopecia Triple Hair Inc Recruiting No outcome recorded
Phase 3 NCT06501924 Comparator Jan → Oct 2025 overdue baldness, male pattern Applied Biology, Inc. Not yet recruiting No outcome recorded
Phase 3 NCT06484881 Comparator Sep → Oct 2024 androgenetic alopecia Applied Biology, Inc. Withdrawn No outcome recorded
Phase 3 NCT04594018 Comparator Feb 2023 → May 2026 overdue androgenetic alopecia EMS Recruiting No outcome recorded
Phase 3 NCT05296863 Background Oct → Dec 2021 androgenetic alopecia Dr. dr. Lili Legiawati, SpKK(K) Completed No outcome recorded
Phase 49 trials
Phase 4 NCT07518342 Comparator Apr 2026 → Jun 2028 expected androgenetic alopecia Assiut University Not yet recruiting No outcome recorded
Phase 4 NCT07459933 Comparator Mar → Sep 2026 expected alopecia areata Jinnah Postgraduate Medical Centre Not yet recruiting No outcome recorded
Phase 4 NCT06043349 Comparator Jun → Sep 2023 androgenetic alopecia Indonesia University Unknown No outcome recorded
Phase 4 NCT04293822 Comparator Jun → Nov 2020 androgenetic alopecia Assiut University Unknown No outcome recorded
Phase 4 NCT04209803 Comparator Dec 2018 → Sep 2020 androgenetic alopecia Kafrelsheikh University Completed No outcome recorded
Phase not applicable11 trials
NCT07536100 Comparator May → Nov 2026 expected androgenetic alopecia Institute of Dermatology, Thailand Recruiting No outcome recorded
NCT07502976 Comparator Jan → Oct 2026 expected androgenetic alopecia Kasr El Aini Hospital Recruiting No outcome recorded
NCT07373054 Comparator Nov 2025 → Jul 2026 overdue androgenetic alopecia Fujian Medical University Union Hospital Recruiting No outcome recorded
NCT06218394 Comparator Dec 2023 → Sep 2024 androgenetic alopecia Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
NCT06218498 Comparator Nov 2023 → Jun 2024 androgenetic alopecia Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded

Evidence & citations 33 cited values

Every value below carries the sentence it was read from. 88 sources stand behind the page.

FieldValueCited text
Known as Minoxidil “This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.” NCT00175617
86

“combination of minoxidil and finasteride” NCT07038941

“5% minoxidil / high dose of finasteride” NCT02824380

“guanfacine, hydralazine, minoxidilNCT00684489

“2 % Minoxidil and /or Finasteride” NCT01643629

NCT01319370

NCT04481412

NCT07264790

NCT00876200

NCT04090801

NCT04594018

NCT00958750

NCT07273799

NCT02275832

NCT03852992

NCT05272462

NCT07502976

NCT07548918

NCT07011485

NCT07529977

NCT02486848

NCT07459933

NCT06501924

NCT06527729

NCT05417308

NCT01900041

NCT06015516

NCT05888922

NCT04209803

NCT07536100

NCT07076706

NCT05636904

NCT07518342

NCT07594678

NCT06813963

NCT05369481

NCT02279823

NCT06043349

NCT02483195

NCT05790941

NCT07373054

NCT01226459

NCT01650272

NCT01924000

NCT06108193

NCT00607477

NCT01672307

NCT06826001

NCT05989165

NCT05587257

NCT01325337

NCT07370519

NCT07080931

NCT03488108

NCT04293822

NCT01655108

NCT01145625

NCT03831334

NCT02460497

NCT00151515

NCT06333600

NCT04207931

NCT01391156

NCT05990400

NCT06924632

NCT02283645

NCT02460289

NCT07435012

NCT04721548

NCT07203599

NCT06679556

NCT07018349

NCT05778825

NCT02280603

NCT03753113

NCT06066827

NCT06218498

NCT05296863

NCT03535233

NCT03528772

NCT05864885

NCT06218394

NCT05827991

NCT06484881

NCT01325350

NCT07012486

NCT07563036

Known as Alopexil ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Alostil ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Loniten ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Lonolox ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Men's rogaine ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Minodyl ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Minoxidil (for men) ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Minoxidil (for women) ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Minoxidil extra strength (for men) ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Minoxidil Forte Minoxidil Forte 5% topical gel 60 gm; Pharmacare Egypt Co., Cairo, Egypt” NCT03528772
Known as Minoximen ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Mintop ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Normoxidil ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as NSC-757106 ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Pierminox ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Prexidil ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Regaine for men ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Regaine for women ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Regaxidil “The reference drug is minoxidil 20 mg/ml (2%) topical solution, marketed in Spain by Industrial Farmacéutica Cantabria, S.A., under the name the trade name of Regaxidil®.” NCT06015516
Known as Riup ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Rogaine ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Rogaine (for men) ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Rogaine (for women) ChEMBL registry synonym — accepted as the source's own label CHEMBL802
Known as Rogaine extra strength (for men) ChEMBL registry synonym — accepted as the source's own label CHEMBL802